Institute for Applied Cancer Science
Neurodegeneration Consortium (NDC)
The Neurodegeneration Consortium (NDC) is a transformative multi-institutional initiative that will advance the study and treatment of Alzheimer’s and other neurodegenerative diseases. The consortium was established with a $25 million gift from the Robert A. and Renee E. Belfer Family Foundation and is a collaboration between MD Anderson, Baylor College of Medicine and the Massachusetts Institute of Technology (MIT). The Belfers’ commitment is contingent on the consortium partners raising a matching $25 million in private philanthropy. Support this transformative venture by donating through the NDC myGiving site now.The consortium’s mission is to identify key molecular targets that cause Alzheimer’s and other neurodegenerative diseases and to rapidly translate these discoveries into treatments.
Why NDC provides hope
While the Alzheimer’s field has traditionally focused on one major theory, the so-called amyloid hypothesis, this research direction has not resulted in any therapeutic options for patients. Additionally, the root cause of neuronal degeneration remains unknown. The consortium is taking an innovative strategy that will focus on alternative hypotheses that include neuronal protection. The goal of the consortium is to employ an innovative research and development infrastructure that will result in changing Alzheimer’s from a terminal diagnosis into a treatable condition.
MD Anderson’s Institute for Applied Cancer Science (IACS) will serve as the drug discovery and development component of the consortium. The consortium will leverage the infrastructure and expertise of the entire Institute, with neurobiology and neuropharmacology groups providing project specific expertise. The neuroscientists within IACS will liaise with researchers at the partner institutions, to move projects towards the selection of clinical candidates, and to prioritize identified targets for future drug discovery efforts.
Why IACS is the logical drug development partner
IACS has developed the functional components necessary develop therapeutics, regardless of the disease target, and the IACS has established fully integrated milestone-driven project teams with over 300-years of drug development experience.